Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Although anxiety and depression have been considered as two distinct entities according to
the diagnostic criteria, anxious depression (comorbid anxiety and depression) is relatively a …

Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as
major depression. It could be optimized by identifying neural biomarkers that trigger therapy …

Deep brain stimulation is a promising treatment for severe depression, but lack of efficacy in
randomized trials raises questions regarding anatomical targeting. We implanted multi-site …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Current medication for anxiety disorders is suboptimal in terms of efficiency and tolerability,
highlighting the need for improved drug treatments. In this review an overview of drugs …

Purpose To assess the pharmacokinetics and safety of pure S-ketamine (esketamine) in
Chinese patients undergoing painless gastroscopy and evaluate the potential advantage of …

Major mood syndromes are among the most common and disabling mental disorders.
However, a lack of clear delineation of their underlying pathophysiological mechanisms is a …

What is known and objective Esketamine is an N‐methyl‐D‐aspartic acid (NMDA) receptor
antagonist, which has stronger sedative and analgesic effects and fewer adverse events …

Background The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults
with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently …